Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 17 of 17 for “"fingolimod"”.
-
Sphingosine-1-Phosphate and Fingolimod (FTY720) Regulate ICl,swell In HL-1 Cardiac Myocytes via Intracellular Binding And Mitochondrial ROS Production
… signaling. S1P and its analog, FTY720 (fingolimod), primarily act via G-protein coupled receptors (S1PR; S1PR1-3 in heart), but several intracellular S1P ligands are known. We investigated how these agents regulate ICl,swell. ICl,swell was elicited by bath S1P (500 nM), FTY720 (S1PR1,3 …
-
The role of regulatory T cells in stroke recovery
… Treg-targeted stroke immunotherapies, namely fingolimod and recombinant pregnancy-specific glycoprotein-1 (rPSG1-Fc). Methods: The effect of fingolimod on Tregs in a mouse model of permanent brain ischaemia was first investigated using a combination of flow cytometry and immunohistochemistry. …
-
PRG4/CD44/PP2A Signaling Axis: A Significant Regulator of Gout Arthritis
… TLR2 agonist and stimulated with MSU crystals. Fingolimod (PP2A activating drug) and febuxostat (XO inhibitor) were assessed for their ability to regulate PP2A and XO activity, UA production, ROS generation and IL-1b secretion. Anti-inflammatory effect of fingolimod was assessed in vivo. …
-
Development of Immune Modulators Targeting Autoimmune Disorders and Pulmonary Injury: Design, Synthesis, and Biological Evaluation of Sphingolipid-Derived Sphingosine-1 Phosphate Receptor 1 Agonists
… research, a synthetic sphingoid derivative – fingolimod – that acts as a competitive receptor expression level downregulator, featuring prolonged prodrug character and undesired receptor promiscuity, remains the prevalent oral treatment for severe autoimmune disorders since its introduction in …
-
Imaging and therapy in multiple sclerosis
… Among patients with RRMS, initial treatment with fingolimod, natalizumab or alemtuzumab was associated with a lower risk of conversion to SPMS compared to initial treatment with glatiramer acetate or interferon beta over a median 5.8 years of follow-up. A lower risk of conversion was also …
-
Role of T Lymphocyte Trafficking in Diabetic Cardiomyopathy
… three related studies: (1) assess the effects of fingolimod (S1P1 receptor modulator) treatment in diabetes-induced myocardial fibrosis in mice; (2) study cardiac fibrosis and dysfunction in diabetes using conditional T-cell S1P1 knockout (TS1P1KO) mice; (3) evaluate the effects of CD4+ T cells …
-
The photoredox-catalysed generation and reaction of alkyl α-amino radicals for α-tertiary amine synthesis
… single step synthesis of the blockbuster drug fingolimod. Mechanistic studies enabled a catalytic cycle to be proposed and highlighted the importance of a key 1,5-HAT process in driving the forward reaction. Subsequently, it was discovered that by employing a chiral amine as a starting …
-
Modular Methods for the Synthesis of α-Tertiary and α-Branched Alkylamines via Visible-Light-Mediated Radical Generation
… synthesis of the multiple sclerosis drug fingolimod (Gilenya), and provided access to a range of unique spirocyclic tetrahydronaphthyridine and tetrahydroquinoline scaffolds. Mechanistic studies inform the proposal of a redox-neutral catalytic cycle involving generation of a key α-amino …
-
IGF2R: A NEW PLAYER IN THE INSULIN LIKE GROWTHFACTOR 2 (IGF2) PATHWAY SUSTAINING ADRENOCORTICAL TUMOURS CELL GROWTH
… we tested two different inhibitors, safingol and fingolimod. The two drugs were able to impair cell proliferation, viability, and cortisol secretion, both on ACC cell lines and primary cultures. Moreover, we compared their antitumoral activity with the current therapeutic strategy for advanced …
-
Determination of Absolute Protein Content of Hepatic CYP4F Enzymes in Human Liver Microsomes Using LC/MS/MS Methodology and Comparison with Immunoquantification and Enzyme Activity
… and xenobiotics (parfuramidine (DB289), DB1230, fingolimod). The CYP3A subfamily of enzymes are known to metabolize a wide variety of physiologically and pharmaceutically important substances. The determination of the absolute enzyme protein content and the inter-individual variability in the …
-
Metabolomic characterization of Multiple Sclerosis
… PPMS); 2) Monitoring of the response to the Fingolimod therapy; 3) To study the protective role of pregnancy on MS progression. Plasma, serum and cerebrospinal fluid (this only for the first study) were collected from selected MS patients and healthy subjects, and Nuclear Magnetic Resonance …
-
Development of Potent Inhibitors of the Sphingosine-1-Phosphate Transporter Spns2 for the Treatment of Multiple Sclerosis
… for the treatment of autoimmune disorders (fingolimod, siponimod, ozanimod, and ponesimod), they typically manifest on-target cardiovascular side-effects. Therefore, the development of novel Spns2 inhibitors is a prudent alternative approach to achieve S1P-mediated lymphopenia. In this …
-
The role of pulmonary innate and adaptive immune responses to helminth infection
… contributed to this immunity, we used the drug Fingolimod (FTY720) to block T cell egress from lymph nodes (LN) to peripheral tissue. T cell egress from the LN was required for resolution of a primary infection but not for secondary infection. The presence of tissue-resident IL-4Rα responsive …
-
The role of pulmonary innate and adaptive immune responses to helminth infection
… contributed to this immunity, we used the drug Fingolimod (FTY720) to block T cell egress from lymph nodes (LN) to peripheral tissue. T cell egress from the LN was required for resolution of a primary infection but not for secondary infection. The presence of tissue-resident IL-4Rα responsive …
-
Role of Protein Phosphatase-2A in Regulating Monocyte Activation by Soluble and Crystalline Uric Acid in Gout
… in cell growth and inflammation. The prodrug Fingolimod (FTY720) and its phosphorylated active metabolite (p-FTY720) activate intracellular PP2A. We hypothesized that monocyte activation by MSU crystals is mediated by a reduction in intracellular PP2A activity and restoring PP2A activity …